CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0398 (clinicaltrials.gov NCT No: NCT01023308)
Title:A Multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma
Principal Investigator:Donna M. Weber
Treatment Agent:Bortezomib; Dexamethasone; Panobinostat
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
panobinostat, bortezomib, and dexamethasone is safe and results in a better
anti-myeloma activity than bortezomib and dexamethasone alone.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase III
Treatment Agents:Bortezomib
Dexamethasone
Panobinostat
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Donna M. Weber
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults